However, even if literature data are available on the use of radiolabeled somatostatin analogues [58,59,60,61,62,63], choline [64,65,66,67,68], PSMA ligands [62,69,70,71,72,73,74] and FAPI [74,75,76,77,78,79] in thyroid cancer; currently, these PET methods are used only in research setting for this purpose [30], except the use of somatostatin receptor PET in medullary thyroid cancer according to existing guidelines [80]. This evidence concerns the gene FOLH1 and medullary thyroid gland carcinoma.